Clinical Impact of New Data From AASLD 2019

November 8-12, 2019; Boston, Massachusetts
This downloadable slideset reviews new, clinically relevant data on viral hepatitis and NAFLD/NASH; topics include risk of HCC in patients with viral hepatitis, HBV and HCV treatment, organ transplant from donors with HCV infection, and novel treatments for NAFLD/NASH.
Ira M. Jacobson, MD
Nancy Reau, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 894 KB
Released: December 2, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Downloadable slides from CCO expert, Dr. Alain H. Litwin, on integrating HCV and HIV prevention and care strategies into addiction care settings

Alain H. Litwin, MD Released: September 18, 2020

Dr. Stefan Zeuzem discusses new viral hepatitis data reported at the 2020 Digital International Liver Congress, in the CCO Infectious Disease podcast

Stefan Zeuzem, MD Released: September 14, 2020

Expert selections of the most important viral hepatitis data from EASL 2020, including HCV elimination and HCV and HBV treatment, provided by CCO

Stefan Zeuzem, MD Released: September 8, 2020

CCO commentary from Anna Christina L. dela Cruz, MD, on the use of quantitative HBsAg and elastography in the management of hepatitis B

Anna Christina L. dela Cruz, MD Released: August 18, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue